A Phase 1 interventional study of Ritlecitinib 20 mg in Alopecia Areata, sponsored by Pfizer. Completed at 9 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.
Among the 17 studies in Alopecia Areata by Pfizer, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 1, and was the 7th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Pfizer · Sites in United States, China, Czechia and 6 more countries
Ages 6–14
Pfizer · Sites in Korea, Republic of
Ages 12+
Pfizer · Sites in United States, Canada, China and 8 more countries
Ages 12+
By country, each count listing its studies:
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2016; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 175 across the 10 interventional studies, 375 across the 6 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Alopecia Areata by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alopecia Areata by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called Ritlecitinib) in children of 6 to \<12 years of age with Alopecia Areata, a condition of scalp hair loss. 12 children with alopecia areata will be participating in this study. All participants will receive study medicine with a dose of 20 milligram (mg) orally once daily for 7 days. 5 blood samples will be collected on day 7 for pharmacokinetic evaluation and 2 blood samples each at screening and on Day 7 will be collected for pharmacodynamic evaluation. Participants will take part in the study for about 10 weeks.
This is an interventional, Pharmacokinetic (PK), Pharmacodynamic (PD), phase 1, open label study in children 6 to less than 12 years of age with ≥50% scalp hair loss due to severe alopecia areata. The purpose of the study is to collect data to support dose selection for subsequent studies in the same population.
Participants will be screened and, if all eligibility criteria are met, will receive the first dose of Investigational product within 28 days after the screening visit.
Participants will receive 20 mg ritlecitinib in one dose, daily, for 7 consecutive days. Blood samples for pharmacodynamic evaluation will be collected on screening and Day 7. Blood samples for pharmacokinetic evaluation will be collected on Day 7 at: 0 hr (pre-dose), 0.5 hr, 1 hr, 3 hrs, and 8 hrs after dosing.
At least 12 evaluable participants with respect to the primary endpoint will be enrolled in the study.
Participants and their parents/legal guardians will be required to visit the study site 3 times during the study (Screening, Day 1 and Day 7) A safety follow-up visit will be conducted by phone, 28 to 35 days after the last dose of ritlecitinib.
Key Inclusion criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Ritlecitinib 20 mg by mouth once daily (QD).
Drug: Ritlecitinib 20 mg
orally administered, Ritlecitinib 20 mg once daily (QD)
Area Under the Plasma Concentration-Time Profile Over the Dosing Interval of 24 Hours, at Steady State (AUC24ss/AUCtau) of Ritlecitinib on Day 7
Linear-log trapezoidal method was used for evaluation. For the calculation of AUCtau, pre-dose concentration of Day 7 was used as an estimate for the concentration of 24 hours post-dose on Day 7.
Time frame: Day 7: 0 (pre-dose), 0.5, 1, 3, 8 and 24 hours [pre-dose concentration was used as an estimate for the concentration of 24 hours post dose]
Maximum Observed Plasma Concentration (Cmax) of Ritlecitinib
Time frame: 0 (pre-dose), 0.5, 1, 3 and 8 hours post-dose on Day 7
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib
Time frame: 0 (pre-dose), 0.5, 1, 3 and 8 hours post-dose on Day 7
Apparent Oral Clearance (CL/F) of Ritlecitinib
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological process. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: 0 (pre-dose), 0.5, 1, 3 and 8 hours post-dose on Day 7
Apparent Volume of Distribution (Vz/F) of Ritlecitinib
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F is influenced by the fraction absorbed.
Time frame: 0 (pre-dose), 0.5, 1, 3 and 8 hours post-dose on Day 7
Elimination Half-Life (t1/2) of Ritlecitinib
Elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by one half at the elimination phase.
Time frame: 0 (pre-dose), 0.5, 1, 3 and 8 hours post-dose on Day 7
Change From Baseline in Interferon Gamma Induced Protein 10 (IP-10) on Day 7
Time frame: Baseline and Day 7
Change From Baseline in T Lymphocytes on Day 7
T lymphocytes included CD3 cells, CD4 T helper lymphocytes and CD8 T cytotoxic lymphocytes.
Time frame: Baseline and Day 7
Change From Baseline in B Lymphocytes on Day 7
B lymphocytes included CD19 cells.
Time frame: Baseline and Day 7
Change From Baseline in Natural Killer (NK) Cells on Day 7
Time frame: Baseline and Day 7
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent were events between first dose to 35 days after last dose, that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Day 1 of dosing up to 35 days after the last dose (maximum up to Day 42)
Number of Participants With Treatment Related AEs
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Relatedness was judged by investigator.
Time frame: Day 1 of dosing up to 35 days after the last dose (maximum up to Day 42)
Number of Participants With Serious AEs (SAEs)
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Day 1 of dosing up to 35 days after the last dose (maximum up to Day 42)
Number of Participants With AEs Leading to Treatment Discontinuation
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Day 1 up to Day 7
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Vital signs evaluation included blood pressure and heart rate measurements. Clinical significance of any vital sign abnormality was judged by investigator.
Time frame: Day 1 up to Day 7
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values
Clinical laboratory parameters included haematology: haemoglobin, haematocrit, red blood cells count, platelet count, white blood cells count, total absolute: neutrophils, eosinophils, monocytes, basophils, lymphocytes; chemistry: urea and creatinine estimated creatinine clearance, glucose (fasting), sodium, potassium, chloride, aspartate aminotransferase (AT), alanine AT, total bilirubin, alkaline phosphatase, albumin, total protein; urinalysis: local dipstick: pH, qualitative: glucose, protein, albuminuria, blood, ketones, nitrites, leukocyte esterase and others. Clinical significance of any laboratory abnormality was judged by investigator.
Time frame: Day 1 up to Day 7
Number of Participants as Per Score for Pediatric Taste Assessment Questionnaire
The pediatric taste questionnaire included 3 questions regarding: 1) Overall Taste (likeability in tase), 2) Overall Mouthfeel (how the medicine felt) and 3) Overall Volume of Medicine (likeability of the amount of medicine). Each question ranged from 1 (most favorable) to 5 (least favorable), higher scores indicates less liking to medicine. Ritlecitinib was provided as capsules; for administration, the capsules were dissolved in water and the contents of the capsule in water were taken according to the dosing administration instructions.
Time frame: Day 1 and 7
| Milestone | Ritlecitinib 20 mg |
|---|---|
| Started | 15 |
| Completed | 14 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | Ritlecitinib 20 mg |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
Linear-log trapezoidal method was used for evaluation. For the calculation of AUCtau, pre-dose concentration of Day 7 was used as an estimate for the concentration of 24 hours post-dose on Day 7.
| Nanogram*hours per milliliter (ng*hr/mL) | Ritlecitinib 20 mg |
|---|---|
| Area Under the Plasma Concentration-Time Profile Over the Dosing Interval of 24 Hours, at Steady State (AUC24ss/AUCtau) of Ritlecitinib on Day 7 | 437.5 ± 30 |
| Nanogram per milliliter (ng/mL) | Ritlecitinib 20 mg |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Ritlecitinib | 208.7 ± 38 |
| Hours | Ritlecitinib 20 mg |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib | 0.500 ± 0.450 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological process. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| Liter per hour (L/hr) | Ritlecitinib 20 mg |
|---|---|
| Apparent Oral Clearance (CL/F) of Ritlecitinib | 45.70 ± 30 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F is influenced by the fraction absorbed.
| Liter | Ritlecitinib 20 mg |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Ritlecitinib | 74.92 ± 23 |
Elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by one half at the elimination phase.
| Hours | Ritlecitinib 20 mg |
|---|---|
| Elimination Half-Life (t1/2) of Ritlecitinib | 1.191 ± 0.10776 |
| Picogram per milliliter (pg/mL) | Ritlecitinib 20 mg |
|---|---|
| Baseline | 121.0 (74.7 to 888.0) |
| Change at Day 7 | -9.9 (-555.0 to 104.0) |
T lymphocytes included CD3 cells, CD4 T helper lymphocytes and CD8 T cytotoxic lymphocytes.
| 10^9 cells per liter | Ritlecitinib 20 mg |
|---|---|
| CD3 cells: Baseline | 1.8 (0.8 to 3.4) |
| CD3 cells: Change at Day 7 | -0.0 (-1.3 to 2.0) |
| CD4 T helper lymphocytes: Baseline | 1.0 (0.6 to 1.6) |
| CD4 T helper lymphocytes: Change at Day 7 | -0.1 (-0.6 to 1.1) |
| CD8 T cytotoxic lymphocytes: Baseline | 0.6 (0.2 to 1.5) |
| CD8 T cytotoxic lymphocytes: Change at Day 7 | 0.0 (-0.6 to 0.8) |
B lymphocytes included CD19 cells.
| 10^6 cells per liter | Ritlecitinib 20 mg |
|---|---|
| Baseline | 439.0 (191.0 to 881.0) |
| Change at Day 7 | -19.0 (-116.0 to 766.0) |
| 10^6 cells per liter | Ritlecitinib 20 mg |
|---|---|
| Baseline | 254.0 (85.0 to 729.0) |
| Change at Day 7 | -25.5 (-318.0 to 627.0) |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent were events between first dose to 35 days after last dose, that were absent before treatment or that worsened relative to pretreatment state.
| Participants | Ritlecitinib 20 mg |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 3 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Relatedness was judged by investigator.
| Participants | Ritlecitinib 20 mg |
|---|---|
| Number of Participants With Treatment Related AEs | 1 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Ritlecitinib 20 mg |
|---|---|
| Number of Participants With Serious AEs (SAEs) | 0 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Ritlecitinib 20 mg |
|---|---|
| Number of Participants With AEs Leading to Treatment Discontinuation | 1 |
Vital signs evaluation included blood pressure and heart rate measurements. Clinical significance of any vital sign abnormality was judged by investigator.
| Participants | Ritlecitinib 20 mg |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | 0 |
Clinical laboratory parameters included haematology: haemoglobin, haematocrit, red blood cells count, platelet count, white blood cells count, total absolute: neutrophils, eosinophils, monocytes, basophils, lymphocytes; chemistry: urea and creatinine estimated creatinine clearance, glucose (fasting), sodium, potassium, chloride, aspartate aminotransferase (AT), alanine AT, total bilirubin, alkaline phosphatase, albumin, total protein; urinalysis: local dipstick: pH, qualitative: glucose, protein, albuminuria, blood, ketones, nitrites, leukocyte esterase and others. Clinical significance of any laboratory abnormality was judged by investigator.
| Participants | Ritlecitinib 20 mg |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values | 0 |
The pediatric taste questionnaire included 3 questions regarding: 1) Overall Taste (likeability in tase), 2) Overall Mouthfeel (how the medicine felt) and 3) Overall Volume of Medicine (likeability of the amount of medicine). Each question ranged from 1 (most favorable) to 5 (least favorable), higher scores indicates less liking to medicine. Ritlecitinib was provided as capsules; for administration, the capsules were dissolved in water and the contents of the capsule in water were taken according to the dosing administration instructions.
| Participants | Ritlecitinib 20 mg |
|---|---|
| Day 1: Taste Score — 1 | 1 |
| Day 1: Taste Score — 2 | 0 |
| Day 1: Taste Score — 3 | 3 |
| Day 1: Taste Score — 4 | 3 |
| Day 1: Taste Score — 5 | 7 |
| Day 1: Mouthfeel Score — 1 | 0 |
| Day 1: Mouthfeel Score — 2 | 5 |
| Day 1: Mouthfeel Score — 3 | 3 |
| Day 1: Mouthfeel Score — 4 | 4 |
| Day 1: Mouthfeel Score — 5 | 2 |
| Day 1: Volume Score — 1 | 2 |
| Day 1: Volume Score — 2 | 5 |
| Day 1: Volume Score — 3 | 2 |
| Day 1: Volume Score — 4 | 2 |
| Day 1: Volume Score — 5 | 3 |
| Day 7: Taste Score — 1 | 0 |
| Day 7: Taste Score — 2 | 1 |
| Day 7: Taste Score — 3 | 4 |
| Day 7: Taste Score — 4 | 2 |
| Day 7: Taste Score — 5 | 7 |
| Day 7: Mouthfeel Score — 1 | 0 |
| Day 7: Mouthfeel Score — 2 | 5 |
| Day 7: Mouthfeel Score — 3 | 3 |
| Day 7: Mouthfeel Score — 4 | 5 |
| Day 7: Mouthfeel Score — 5 | 1 |
| Day 7: Volume Score — 1 | 1 |
| Day 7: Volume Score — 2 | 6 |
| Day 7: Volume Score — 3 | 2 |
| Day 7: Volume Score — 4 | 1 |
| Day 7: Volume Score — 5 | 4 |
Collected over Day 1 up to 35 days after last dose (maximum up to Day 42). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ritlecitinib 20 mg QD | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) |
| Event | Ritlecitinib 20 mg QD |
|---|---|
| NauseaGastrointestinal disorders | 1/15 |
| VomitingGastrointestinal disorders | 1/15 |
| UrticariaSkin and subcutaneous tissue disorders | 1/15 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/15 |
All participants who were enrolled in the study and were assigned to study intervention.
| Age, Continuous(Years) | Ritlecitinib 20 mg |
|---|---|
| Mean | 8.5 ± 1.60 |
| Sex: Female, Male(Participants) | Ritlecitinib 20 mg |
|---|---|
| Female | 12 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Ritlecitinib 20 mg |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Ritlecitinib 20 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 13 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Mar 2023 to primary completion in Aug 2023, 5 months.
Results were first posted in Oct 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600